SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels

被引:80
作者
Suga, Takayoshi [1 ,2 ]
Kikuchi, Osamu [1 ]
Kobayashi, Masaki [1 ]
Matsui, Sho [1 ]
Yokota-Hashimoto, Hiromi [1 ]
Wada, Eri [1 ]
Kohno, Daisuke [1 ]
Sasaki, Tsutomu [1 ]
Takeuchi, Kazusane [3 ]
Kakizaki, Satoru [2 ]
Yamada, Masanobu [2 ]
Kitamura, Tadahiro [1 ]
机构
[1] Gunma Univ, Inst Mol & Cellular Regulat, Metab Signal Res Ctr, 3-39-15 Showa Machi, Maebashi, Gunma 3718512, Japan
[2] Gunma Univ, Dept Med & Mol Sci, Grad Sch Med, Maebashi, Gunma, Japan
[3] Cosmic Corp Co Ltd, Bunkyo Ku, Tokyo, Japan
关键词
Alpha cell; Diabetes; Sodium glucose cotransporter; SGLT; Phloretin; Sotagliflozin; INTESTINAL GLUCOSE-ABSORPTION; INADEQUATE GLYCEMIC CONTROL; FATTY LIVER-DISEASE; GLP-1; SECRETION; DOUBLE-BLIND; CANCER CELLS; ADD-ON; TYPE-2; DAPAGLIFLOZIN; CANAGLIFLOZIN;
D O I
10.1016/j.molmet.2018.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase glucagon secretion via direct inhibition of SGLT2 in pancreatic a cells. The role of SGLT1 in alpha cells is also unclear. We aimed to elucidate these points that are important not only for basic research but also for clinical insight. Methods: Plasma glucagon levels were assessed in the high-fat, high-sucrose diet (HFHSD) fed C57BL/6J mice treated with dapagliflozin or canagliflozin. RT-PCR, RNA sequence, and immunohistochemistry were conducted to test the expression of SGLT1 and SGLT2 in alpha cells. We also used alpha TC1 cells and mouse islets to investigate the molecular mechanism by which SGLT1 modulates glucagon secretion. Results: Dapagliflozin, but not canagliflozin, increased plasma glucagon levels in HFHSD fed mice. SGLT1 and glucose transporter 1 (GLUT1), but not SGLT2, were expressed in aTC1 cells, mouse islets and human islets. A glucose clamp study revealed that the plasma glucagon increase associated with dapagliflozin could be explained as a response to acute declines in blood glucose. Canagliflozin suppressed glucagon secretion by inhibiting SGLT1 in a cells; consequently, plasma glucagon did not increase with canagliflozin, even though blood glucose declined. SGLT1 effect on glucagon secretion depended on glucose transport, but not glucose metabolism. Islets from HFHSD and db/db mice displayed higher SGLT1 mRNA levels and lower GLUT1 mRNA levels than the islets from control mice. These expression levels were associated with higher glucagon secretion. Furthermore, SGLT1 inhibitor and siRNA against SGLT1 suppressed glucagon secretion in isolated islets. Conclusions: These data suggested that a novel mechanism regulated glucagon secretion through SGLT1 in a cells. This finding possibly explained the distinct effects of dapagliflozin and canagliflozin on plasma glucagon levels in mice. (C) 2018 The Authors. Published by Elsevier GmbH.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 51 条
[1]   Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].
Bailey, Clifford J. ;
Gross, Jorge L. ;
Pieters, Anne ;
Bastien, Arnaud ;
List, James F. .
LANCET, 2010, 375 (9733) :2223-2233
[2]   Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans [J].
Bak, Monika J. ;
Albrechtsen, Nicolai Wewer ;
Pedersen, Jens ;
Hartmann, Bolette ;
Christensen, Mikkel ;
Vilsboll, Tina ;
Knop, Filip K. ;
Deacon, Carolyn F. ;
Dragsted, Lars O. ;
Holst, Jens J. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 170 (04) :529-538
[3]   ROLE OF HYPERGLUCAGONEMIA IN MAINTENANCE OF INCREASED RATES OF HEPATIC GLUCOSE OUTPUT IN TYPE-II DIABETICS [J].
BARON, AD ;
SCHAEFFER, L ;
SHRAGG, P ;
KOLTERMAN, OG .
DIABETES, 1987, 36 (03) :274-283
[4]   Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion [J].
Bonner, Caroline ;
Kerr-Conte, Julie ;
Gmyr, Valery ;
Queniat, Gurvan ;
Moerman, Ericka ;
Thevenet, Julien ;
Beaucamps, Cedric ;
Delalleau, Nathalie ;
Popescu, Iuliana ;
Malaisse, Willy J. ;
Sener, Abdullah ;
Deprez, Benoit ;
Abderrahmani, Amar ;
Staels, Bart ;
Pattou, Francois .
NATURE MEDICINE, 2015, 21 (05) :512-U139
[5]   Islet α cells and glucagon-critical regulators of energy homeostasis [J].
Campbell, Jonathan E. ;
Drucker, Daniel J. .
NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (06) :329-338
[6]   Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas [J].
de Heer, J. ;
Rasmussen, C. ;
Coy, D. H. ;
Holst, J. J. .
DIABETOLOGIA, 2008, 51 (12) :2263-2270
[7]   GLP-1 Inhibits and Adrenaline Stimulates Glucagon Release by Differential Modulation of N- and L-Type Ca2+ Channel-Dependent Exocytosis [J].
De Marinis, Yang Z. ;
Salehi, Albert ;
Ward, Caroline E. ;
Zhang, Quan ;
Abdulkader, Fernando ;
Bengtsson, Martin ;
Braha, Orit ;
Braun, Matthias ;
Ramracheya, Reshma ;
Amisten, Stefan ;
Habib, Abdella M. ;
Moritoh, Yusuke ;
Zhang, Enming ;
Reimann, Frank ;
Rosengren, Anders H. ;
Shibasaki, Tadao ;
Gribble, Fiona ;
Renstrom, Erik ;
Seino, Susumu ;
Eliasson, Lena ;
Rorsman, Patrik .
CELL METABOLISM, 2010, 11 (06) :543-553
[8]   TEST OF HYPOTHESIS THAT RATE OF FALL IN GLUCOSE CONCENTRATION TRIGGERS COUNTER-REGULATORY HORMONAL RESPONSES IN MAN [J].
DEFRONZO, RA ;
ANDRES, R ;
BLEDSOE, TA ;
BODEN, G ;
FALOONA, GA ;
TOBIN, JD .
DIABETES, 1977, 26 (05) :445-452
[9]   Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus [J].
Devineni, Damayanthi ;
Curtin, Christopher R. ;
Polidori, David ;
Gutierrez, Maria J. ;
Murphy, Joseph ;
Rusch, Sarah ;
Rothenberg, Paul L. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (06) :601-610
[10]   Pharmacological aspects of the safety of gliflozins [J].
Faillie, Jean-Luc .
PHARMACOLOGICAL RESEARCH, 2017, 118 :71-81